The pharmaceutical sector growth is fuelled by blockbuster drugs. 15 blockbusters lose patent protection in 2002 affecting US$30 B in revenues. This article focuses on the increasing willingness of major pharma companies to pay a premium price for products with more immediate market potential to help bolster flagging product pipelines. The article also scrutinizes some of deals with biotech companies whereby major pharma is hoping to draw significant revenues.